OQROSign up free
Politician trade (House)

Regeneron Pharmaceuticals (REGN): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Regeneron Pharmaceuticals in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
27 days
Disclosure lag
Traded
Nov 18, 2025
Disclosed
Dec 15, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 25, 2025FDAFDA drug approval: Evkeeza
  2. Oct 6, 2025Company filing · Form 8-K · ResultsReported its results
  3. Oct 8, 2025FDAFDA drug approval: Libtayo
  4. Oct 9, 2025FDAFDA drug approval: Praluent
  5. Oct 28, 2025Company filing · Form 8-K · ResultsReported its results
  6. Oct 29, 2025FDAFDA drug approval: Libtayo
  7. Oct 29, 2025Insider · 1 personInsiders: 6 sales (~$4.3M)
  8. Nov 7, 2025InsiderOfficer sold ~$281K of REGN shares in the open market
  9. Nov 18, 2025 · this disclosureCongressDisclosed purchase of REGN — reported range $1,001 - $15,000

What came next

  1. Nov 19, 2025FDAFDA drug approval: Eylea HD
  2. Nov 20, 2025InsiderDirector sold ~$570K of REGN shares in the open market
  3. Jan 7, 2026InsiderDirector sold ~$1.2M of REGN shares in the open market
  4. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  5. Jan 30, 2026Company filing · Form 8-K · ResultsReported its results
  6. Feb 9, 2026Insider · 2 peopleInsiders: 24 sales (~$1.7M)
  7. Feb 12, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  8. Feb 19, 2026Insider · 1 personInsiders: 11 sales (~$1.3M)
  9. Feb 23, 2026FDAFDA drug approval: Dupixent
  10. Mar 2, 2026Insider · 1 personInsiders: 13 sales (~$79K)
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 73 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)

The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.

How this filing works

Explore the data

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data